Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant

Prospective Analysis of the Patterns of Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Autologous/Allogeneic Stem Cell Transplant

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00231712

Enrollment

Registered

2005-10-04

Start date

2005-03-31

Completion date

2009-02-28

Last updated

2006-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Medulloblastoma

Keywords

prospective analysis of immune function,, spectratype, immunoscope, TREC analysis, solid tumor

Brief summary

The purpose of this study is to conduct an analysis of the influences of 1. conventional chemotherapy 2. high-dose chemotherapy followed by autologous stem cell transplant 3. high-dose chemotherapy followed by allogeneic stem cell transplant on the recovery of the immune system. Detailed analysis will help to better understand the pathways of recovery of the immune system following chemotherapy as well as the pathways of recovery of the immune system following autologous or allogeneic stem cell transplantation.

Detailed description

Detailed analysis will be performed at preselected time points following therapy by * standard flow cytometry in combination with intracellular cytokine/antigen staining * spectratype analysis * TREC assays

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

0 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute leukemia treated according to current ALL-BFM 2002 protocol * Solid tumor treated according to current GPOH-protocol * Medulloblastoma treated according to HIT-2000 protocol * High-dose chemotherapy followed by autologous stem cell transplantation * High-dose chemotherapy followed by allogeneic stem cell transplantation * Written consent according to our institutional guidelines

Exclusion criteria

* No written consent

Countries

Germany

Contacts

Primary ContactPaul G Schlegel, MD

schlegel@mail.uni-wuerzburg.de+49 - 931 - 201 - 27831

Backup ContactBeate Winkler, MD

winkler_b@klinik.uni-wuerzburg.de49 - 931 - 201 - 27831

Outcome results